Dr. Pavle Repovic, MD, PHD

Medicare patients and services

Medicare patients, 2024

86

Services billed

250

Patients’ average age

66

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 8 companies reported 242 payments worth $225,901 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Washington →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 6 companies. The companies reported $1,317,108 in research payments for these studies, mostly to the institutions running them.

• A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
  E.r. Squibb & Sons, L.l.c.
• A Phase 1, Multicenter, Single-arm, Dose-escalation Study Of CC-97540 (BMS-986353), CD19-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, Evaluating Safety and Tolerability in Participants with Autoimmune Neuro…
  Celgene Corporation
• A Pilot Open-Label, Randomized, Multi-Center, Parall el-Arm, of Acute vs Delay Ofatumumab Treatment d uring an Acute Multiple Sclerosis Relapse
  Novartis Pharmaceuticals Corporation
• A phase iii study to evaluate the efficacy and safety of fenebrutinib in adults with progressive ms
  Genentech, Inc.
• SARS-CoV-2 Vaccination in Individuals with Multiple Sclerosis treated with natalizumab, diroximel fumarate or ocrelizumab: An Observational Study on Immunogenicity and Safety
  Biogen, Inc.
• Assessing disease activity in minority patients with relapsing multiple sclerosis using Ocrelizumab
  Genentech, Inc.
• Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)
  Genzyme Corporation · Completed · NCT04410978
• OCARINA I
  Genentech, Inc.
• Phase III study of Satralizumab in AE
  Genentech, Inc.
• An open-label, single-arm 4-year study to evaluate effectiveness and safety of ocrelizumab treatment in patients with progressive multiple sclerosis
  Genentech, Inc.

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Neurology clinicians in Seattle

• Nandini S. Abburi
• Ban Alamin, MD
• Aws Alawi, M.D.
• Anik J. Amin, M.D.
• Raima M. Amin, M.D.
• Alexander J. Arnold, M.D.
• Denis Balaban, MD
• Phillip A. Ballard JR., MD